0061: Arrhythmic storm in the early phase of Heart Mate® II device implantation. Incidence, risk factors and management

Rhythmic complications seem common after left ventricular (LV) assist device (LVAD), especially in the early phase of implantation (<30 days). We sought to identify the incidence and risk factors of arrhythmic storm (AS) occuring after Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, C...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Corré, Jérôme [verfasserIn] Sacher, Frédéric Derval, Nicolas Calderon, Joachim Barandon, Laurent Picard, François Haissaguerre, Michel Jais, Pierre Santos, Pierre Dos

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2016transfer abstract

Übergeordnetes Werk:	Enthalten in: A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier - Guan, Xiangyang ELSEVIER, 2021, Amsterdam [u.a.]
Übergeordnetes Werk:	volume:8 ; year:2016 ; number:1 ; pages:37

Links:	Volltext

DOI / URN:	10.1016/S1878-6480(16)30115-X

Katalog-ID:	ELV019379188

Internformat


LEADER	01000caa a22002652 4500
001	ELV019379188
003	DE-627
005	20230625125841.0
007	cr uuu---uuuuu
008	180603s2016 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/S1878-6480(16)30115-X \|2 doi
028	5	2	\|a GBVA2016011000015.pica
035			\|a (DE-627)ELV019379188
035			\|a (ELSEVIER)S1878-6480(16)30115-X
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0		\|a 610
082	0	4	\|a 610 \|q DE-600
082	0	4	\|a 380 \|q VZ
084			\|a 55.82 \|2 bkl
100	1		\|a Corré, Jérôme \|e verfasserin \|4 aut
245	1	0	\|a 0061: Arrhythmic storm in the early phase of Heart Mate® II device implantation. Incidence, risk factors and management
264		1	\|c 2016transfer abstract
336			\|a nicht spezifiziert \|b zzz \|2 rdacontent
337			\|a nicht spezifiziert \|b z \|2 rdamedia
338			\|a nicht spezifiziert \|b zu \|2 rdacarrier
520			\|a Rhythmic complications seem common after left ventricular (LV) assist device (LVAD), especially in the early phase of implantation (<30 days). We sought to identify the incidence and risk factors of arrhythmic storm (AS) occuring after Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, CA, USA) implantation. All patients with HM2 implanted in our institution were included. All clinical and ultrasound data were restrospectively collected. Each patient was regurlarly followed until the end of data collection in April 2015. From January 2008 to December 2014, forty-three patients (39 male, 57±11 yo) with severe myocardiopathy (LV Ejection Fraction of 20±5%), mainly ischemic (74%), in bridge to cardiac transplantation (72%), were included. Before implantation, 20 had ICD (16 for prophylaxic indication) and 13 had a prior history of sustained ventricular tachycardia (VT). The overall mortality rate was 60% with a mean follow-up of 18±18 months. 12 patients experienced AS in the first 30 days after implantation, with a median delay of 9±8 days. Early AS often occured in heavier patients (81 vs 69kgs, p<0.05) or with larger body surface area (1.99 vs 1.81m2, p<0.01), in patients with prior sustained VT (50% vs 22%, p=0.08) or long-term treated by betablocker therapy (75% vs 45%, p=0.09). The cardiomyopathy etiology, the indication of assistance or the emergy of implantation were not associated with early AS, as an AS occuring just prior LVAD implantation (11 patients). No AS occured under a Betablocker therapy. VT ablation was performed in 10 patients under assistance. The substrate of VT was not related to HM2 cannula. Arrhythmic storm are frequent (28%) in the early period of HM II implantation.
520			\|a Rhythmic complications seem common after left ventricular (LV) assist device (LVAD), especially in the early phase of implantation (<30 days). We sought to identify the incidence and risk factors of arrhythmic storm (AS) occuring after Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, CA, USA) implantation. All patients with HM2 implanted in our institution were included. All clinical and ultrasound data were restrospectively collected. Each patient was regurlarly followed until the end of data collection in April 2015. From January 2008 to December 2014, forty-three patients (39 male, 57±11 yo) with severe myocardiopathy (LV Ejection Fraction of 20±5%), mainly ischemic (74%), in bridge to cardiac transplantation (72%), were included. Before implantation, 20 had ICD (16 for prophylaxic indication) and 13 had a prior history of sustained ventricular tachycardia (VT). The overall mortality rate was 60% with a mean follow-up of 18±18 months. 12 patients experienced AS in the first 30 days after implantation, with a median delay of 9±8 days. Early AS often occured in heavier patients (81 vs 69kgs, p<0.05) or with larger body surface area (1.99 vs 1.81m2, p<0.01), in patients with prior sustained VT (50% vs 22%, p=0.08) or long-term treated by betablocker therapy (75% vs 45%, p=0.09). The cardiomyopathy etiology, the indication of assistance or the emergy of implantation were not associated with early AS, as an AS occuring just prior LVAD implantation (11 patients). No AS occured under a Betablocker therapy. VT ablation was performed in 10 patients under assistance. The substrate of VT was not related to HM2 cannula. Arrhythmic storm are frequent (28%) in the early period of HM II implantation.
700	1		\|a Sacher, Frédéric \|4 oth
700	1		\|a Derval, Nicolas \|4 oth
700	1		\|a Calderon, Joachim \|4 oth
700	1		\|a Barandon, Laurent \|4 oth
700	1		\|a Picard, François \|4 oth
700	1		\|a Haissaguerre, Michel \|4 oth
700	1		\|a Jais, Pierre \|4 oth
700	1		\|a Santos, Pierre Dos \|4 oth
773	0	8	\|i Enthalten in \|n Elsevier Masson \|a Guan, Xiangyang ELSEVIER \|t A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier \|d 2021 \|g Amsterdam [u.a.] \|w (DE-627)ELV006385559
773	1	8	\|g volume:8 \|g year:2016 \|g number:1 \|g pages:37
856	4	0	\|u https://doi.org/10.1016/S1878-6480(16)30115-X \|3 Volltext
912			\|a GBV_USEFLAG_U
912			\|a GBV_ELV
912			\|a SYSFLAG_U
936	b	k	\|a 55.82 \|j Güterverkehr \|q VZ
951			\|a AR
952			\|d 8 \|j 2016 \|e 1 \|h 37
953			\|2 045F \|a 610

Indexfelder

author_variant	j c jc
matchkey_str	corrjrmesacherfrdricdervalnicolascaldero:2016----:01rhtmctritealpaefermtidvcipattoicdn
hierarchy_sort_str	2016transfer abstract
bklnumber	55.82
publishDate	2016
allfields	10.1016/S1878-6480(16)30115-X doi GBVA2016011000015.pica (DE-627)ELV019379188 (ELSEVIER)S1878-6480(16)30115-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 380 VZ 55.82 bkl Corré, Jérôme verfasserin aut 0061: Arrhythmic storm in the early phase of Heart Mate® II device implantation. Incidence, risk factors and management 2016transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Rhythmic complications seem common after left ventricular (LV) assist device (LVAD), especially in the early phase of implantation (<30 days). We sought to identify the incidence and risk factors of arrhythmic storm (AS) occuring after Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, CA, USA) implantation. All patients with HM2 implanted in our institution were included. All clinical and ultrasound data were restrospectively collected. Each patient was regurlarly followed until the end of data collection in April 2015. From January 2008 to December 2014, forty-three patients (39 male, 57±11 yo) with severe myocardiopathy (LV Ejection Fraction of 20±5%), mainly ischemic (74%), in bridge to cardiac transplantation (72%), were included. Before implantation, 20 had ICD (16 for prophylaxic indication) and 13 had a prior history of sustained ventricular tachycardia (VT). The overall mortality rate was 60% with a mean follow-up of 18±18 months. 12 patients experienced AS in the first 30 days after implantation, with a median delay of 9±8 days. Early AS often occured in heavier patients (81 vs 69kgs, p<0.05) or with larger body surface area (1.99 vs 1.81m2, p<0.01), in patients with prior sustained VT (50% vs 22%, p=0.08) or long-term treated by betablocker therapy (75% vs 45%, p=0.09). The cardiomyopathy etiology, the indication of assistance or the emergy of implantation were not associated with early AS, as an AS occuring just prior LVAD implantation (11 patients). No AS occured under a Betablocker therapy. VT ablation was performed in 10 patients under assistance. The substrate of VT was not related to HM2 cannula. Arrhythmic storm are frequent (28%) in the early period of HM II implantation. Rhythmic complications seem common after left ventricular (LV) assist device (LVAD), especially in the early phase of implantation (<30 days). We sought to identify the incidence and risk factors of arrhythmic storm (AS) occuring after Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, CA, USA) implantation. All patients with HM2 implanted in our institution were included. All clinical and ultrasound data were restrospectively collected. Each patient was regurlarly followed until the end of data collection in April 2015. From January 2008 to December 2014, forty-three patients (39 male, 57±11 yo) with severe myocardiopathy (LV Ejection Fraction of 20±5%), mainly ischemic (74%), in bridge to cardiac transplantation (72%), were included. Before implantation, 20 had ICD (16 for prophylaxic indication) and 13 had a prior history of sustained ventricular tachycardia (VT). The overall mortality rate was 60% with a mean follow-up of 18±18 months. 12 patients experienced AS in the first 30 days after implantation, with a median delay of 9±8 days. Early AS often occured in heavier patients (81 vs 69kgs, p<0.05) or with larger body surface area (1.99 vs 1.81m2, p<0.01), in patients with prior sustained VT (50% vs 22%, p=0.08) or long-term treated by betablocker therapy (75% vs 45%, p=0.09). The cardiomyopathy etiology, the indication of assistance or the emergy of implantation were not associated with early AS, as an AS occuring just prior LVAD implantation (11 patients). No AS occured under a Betablocker therapy. VT ablation was performed in 10 patients under assistance. The substrate of VT was not related to HM2 cannula. Arrhythmic storm are frequent (28%) in the early period of HM II implantation. Sacher, Frédéric oth Derval, Nicolas oth Calderon, Joachim oth Barandon, Laurent oth Picard, François oth Haissaguerre, Michel oth Jais, Pierre oth Santos, Pierre Dos oth Enthalten in Elsevier Masson Guan, Xiangyang ELSEVIER A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier 2021 Amsterdam [u.a.] (DE-627)ELV006385559 volume:8 year:2016 number:1 pages:37 https://doi.org/10.1016/S1878-6480(16)30115-X Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 55.82 Güterverkehr VZ AR 8 2016 1 37 045F 610
spelling	10.1016/S1878-6480(16)30115-X doi GBVA2016011000015.pica (DE-627)ELV019379188 (ELSEVIER)S1878-6480(16)30115-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 380 VZ 55.82 bkl Corré, Jérôme verfasserin aut 0061: Arrhythmic storm in the early phase of Heart Mate® II device implantation. Incidence, risk factors and management 2016transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Rhythmic complications seem common after left ventricular (LV) assist device (LVAD), especially in the early phase of implantation (<30 days). We sought to identify the incidence and risk factors of arrhythmic storm (AS) occuring after Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, CA, USA) implantation. All patients with HM2 implanted in our institution were included. All clinical and ultrasound data were restrospectively collected. Each patient was regurlarly followed until the end of data collection in April 2015. From January 2008 to December 2014, forty-three patients (39 male, 57±11 yo) with severe myocardiopathy (LV Ejection Fraction of 20±5%), mainly ischemic (74%), in bridge to cardiac transplantation (72%), were included. Before implantation, 20 had ICD (16 for prophylaxic indication) and 13 had a prior history of sustained ventricular tachycardia (VT). The overall mortality rate was 60% with a mean follow-up of 18±18 months. 12 patients experienced AS in the first 30 days after implantation, with a median delay of 9±8 days. Early AS often occured in heavier patients (81 vs 69kgs, p<0.05) or with larger body surface area (1.99 vs 1.81m2, p<0.01), in patients with prior sustained VT (50% vs 22%, p=0.08) or long-term treated by betablocker therapy (75% vs 45%, p=0.09). The cardiomyopathy etiology, the indication of assistance or the emergy of implantation were not associated with early AS, as an AS occuring just prior LVAD implantation (11 patients). No AS occured under a Betablocker therapy. VT ablation was performed in 10 patients under assistance. The substrate of VT was not related to HM2 cannula. Arrhythmic storm are frequent (28%) in the early period of HM II implantation. Rhythmic complications seem common after left ventricular (LV) assist device (LVAD), especially in the early phase of implantation (<30 days). We sought to identify the incidence and risk factors of arrhythmic storm (AS) occuring after Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, CA, USA) implantation. All patients with HM2 implanted in our institution were included. All clinical and ultrasound data were restrospectively collected. Each patient was regurlarly followed until the end of data collection in April 2015. From January 2008 to December 2014, forty-three patients (39 male, 57±11 yo) with severe myocardiopathy (LV Ejection Fraction of 20±5%), mainly ischemic (74%), in bridge to cardiac transplantation (72%), were included. Before implantation, 20 had ICD (16 for prophylaxic indication) and 13 had a prior history of sustained ventricular tachycardia (VT). The overall mortality rate was 60% with a mean follow-up of 18±18 months. 12 patients experienced AS in the first 30 days after implantation, with a median delay of 9±8 days. Early AS often occured in heavier patients (81 vs 69kgs, p<0.05) or with larger body surface area (1.99 vs 1.81m2, p<0.01), in patients with prior sustained VT (50% vs 22%, p=0.08) or long-term treated by betablocker therapy (75% vs 45%, p=0.09). The cardiomyopathy etiology, the indication of assistance or the emergy of implantation were not associated with early AS, as an AS occuring just prior LVAD implantation (11 patients). No AS occured under a Betablocker therapy. VT ablation was performed in 10 patients under assistance. The substrate of VT was not related to HM2 cannula. Arrhythmic storm are frequent (28%) in the early period of HM II implantation. Sacher, Frédéric oth Derval, Nicolas oth Calderon, Joachim oth Barandon, Laurent oth Picard, François oth Haissaguerre, Michel oth Jais, Pierre oth Santos, Pierre Dos oth Enthalten in Elsevier Masson Guan, Xiangyang ELSEVIER A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier 2021 Amsterdam [u.a.] (DE-627)ELV006385559 volume:8 year:2016 number:1 pages:37 https://doi.org/10.1016/S1878-6480(16)30115-X Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 55.82 Güterverkehr VZ AR 8 2016 1 37 045F 610
allfields_unstemmed	10.1016/S1878-6480(16)30115-X doi GBVA2016011000015.pica (DE-627)ELV019379188 (ELSEVIER)S1878-6480(16)30115-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 380 VZ 55.82 bkl Corré, Jérôme verfasserin aut 0061: Arrhythmic storm in the early phase of Heart Mate® II device implantation. Incidence, risk factors and management 2016transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Rhythmic complications seem common after left ventricular (LV) assist device (LVAD), especially in the early phase of implantation (<30 days). We sought to identify the incidence and risk factors of arrhythmic storm (AS) occuring after Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, CA, USA) implantation. All patients with HM2 implanted in our institution were included. All clinical and ultrasound data were restrospectively collected. Each patient was regurlarly followed until the end of data collection in April 2015. From January 2008 to December 2014, forty-three patients (39 male, 57±11 yo) with severe myocardiopathy (LV Ejection Fraction of 20±5%), mainly ischemic (74%), in bridge to cardiac transplantation (72%), were included. Before implantation, 20 had ICD (16 for prophylaxic indication) and 13 had a prior history of sustained ventricular tachycardia (VT). The overall mortality rate was 60% with a mean follow-up of 18±18 months. 12 patients experienced AS in the first 30 days after implantation, with a median delay of 9±8 days. Early AS often occured in heavier patients (81 vs 69kgs, p<0.05) or with larger body surface area (1.99 vs 1.81m2, p<0.01), in patients with prior sustained VT (50% vs 22%, p=0.08) or long-term treated by betablocker therapy (75% vs 45%, p=0.09). The cardiomyopathy etiology, the indication of assistance or the emergy of implantation were not associated with early AS, as an AS occuring just prior LVAD implantation (11 patients). No AS occured under a Betablocker therapy. VT ablation was performed in 10 patients under assistance. The substrate of VT was not related to HM2 cannula. Arrhythmic storm are frequent (28%) in the early period of HM II implantation. Rhythmic complications seem common after left ventricular (LV) assist device (LVAD), especially in the early phase of implantation (<30 days). We sought to identify the incidence and risk factors of arrhythmic storm (AS) occuring after Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, CA, USA) implantation. All patients with HM2 implanted in our institution were included. All clinical and ultrasound data were restrospectively collected. Each patient was regurlarly followed until the end of data collection in April 2015. From January 2008 to December 2014, forty-three patients (39 male, 57±11 yo) with severe myocardiopathy (LV Ejection Fraction of 20±5%), mainly ischemic (74%), in bridge to cardiac transplantation (72%), were included. Before implantation, 20 had ICD (16 for prophylaxic indication) and 13 had a prior history of sustained ventricular tachycardia (VT). The overall mortality rate was 60% with a mean follow-up of 18±18 months. 12 patients experienced AS in the first 30 days after implantation, with a median delay of 9±8 days. Early AS often occured in heavier patients (81 vs 69kgs, p<0.05) or with larger body surface area (1.99 vs 1.81m2, p<0.01), in patients with prior sustained VT (50% vs 22%, p=0.08) or long-term treated by betablocker therapy (75% vs 45%, p=0.09). The cardiomyopathy etiology, the indication of assistance or the emergy of implantation were not associated with early AS, as an AS occuring just prior LVAD implantation (11 patients). No AS occured under a Betablocker therapy. VT ablation was performed in 10 patients under assistance. The substrate of VT was not related to HM2 cannula. Arrhythmic storm are frequent (28%) in the early period of HM II implantation. Sacher, Frédéric oth Derval, Nicolas oth Calderon, Joachim oth Barandon, Laurent oth Picard, François oth Haissaguerre, Michel oth Jais, Pierre oth Santos, Pierre Dos oth Enthalten in Elsevier Masson Guan, Xiangyang ELSEVIER A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier 2021 Amsterdam [u.a.] (DE-627)ELV006385559 volume:8 year:2016 number:1 pages:37 https://doi.org/10.1016/S1878-6480(16)30115-X Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 55.82 Güterverkehr VZ AR 8 2016 1 37 045F 610
allfieldsGer	10.1016/S1878-6480(16)30115-X doi GBVA2016011000015.pica (DE-627)ELV019379188 (ELSEVIER)S1878-6480(16)30115-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 380 VZ 55.82 bkl Corré, Jérôme verfasserin aut 0061: Arrhythmic storm in the early phase of Heart Mate® II device implantation. Incidence, risk factors and management 2016transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Rhythmic complications seem common after left ventricular (LV) assist device (LVAD), especially in the early phase of implantation (<30 days). We sought to identify the incidence and risk factors of arrhythmic storm (AS) occuring after Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, CA, USA) implantation. All patients with HM2 implanted in our institution were included. All clinical and ultrasound data were restrospectively collected. Each patient was regurlarly followed until the end of data collection in April 2015. From January 2008 to December 2014, forty-three patients (39 male, 57±11 yo) with severe myocardiopathy (LV Ejection Fraction of 20±5%), mainly ischemic (74%), in bridge to cardiac transplantation (72%), were included. Before implantation, 20 had ICD (16 for prophylaxic indication) and 13 had a prior history of sustained ventricular tachycardia (VT). The overall mortality rate was 60% with a mean follow-up of 18±18 months. 12 patients experienced AS in the first 30 days after implantation, with a median delay of 9±8 days. Early AS often occured in heavier patients (81 vs 69kgs, p<0.05) or with larger body surface area (1.99 vs 1.81m2, p<0.01), in patients with prior sustained VT (50% vs 22%, p=0.08) or long-term treated by betablocker therapy (75% vs 45%, p=0.09). The cardiomyopathy etiology, the indication of assistance or the emergy of implantation were not associated with early AS, as an AS occuring just prior LVAD implantation (11 patients). No AS occured under a Betablocker therapy. VT ablation was performed in 10 patients under assistance. The substrate of VT was not related to HM2 cannula. Arrhythmic storm are frequent (28%) in the early period of HM II implantation. Rhythmic complications seem common after left ventricular (LV) assist device (LVAD), especially in the early phase of implantation (<30 days). We sought to identify the incidence and risk factors of arrhythmic storm (AS) occuring after Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, CA, USA) implantation. All patients with HM2 implanted in our institution were included. All clinical and ultrasound data were restrospectively collected. Each patient was regurlarly followed until the end of data collection in April 2015. From January 2008 to December 2014, forty-three patients (39 male, 57±11 yo) with severe myocardiopathy (LV Ejection Fraction of 20±5%), mainly ischemic (74%), in bridge to cardiac transplantation (72%), were included. Before implantation, 20 had ICD (16 for prophylaxic indication) and 13 had a prior history of sustained ventricular tachycardia (VT). The overall mortality rate was 60% with a mean follow-up of 18±18 months. 12 patients experienced AS in the first 30 days after implantation, with a median delay of 9±8 days. Early AS often occured in heavier patients (81 vs 69kgs, p<0.05) or with larger body surface area (1.99 vs 1.81m2, p<0.01), in patients with prior sustained VT (50% vs 22%, p=0.08) or long-term treated by betablocker therapy (75% vs 45%, p=0.09). The cardiomyopathy etiology, the indication of assistance or the emergy of implantation were not associated with early AS, as an AS occuring just prior LVAD implantation (11 patients). No AS occured under a Betablocker therapy. VT ablation was performed in 10 patients under assistance. The substrate of VT was not related to HM2 cannula. Arrhythmic storm are frequent (28%) in the early period of HM II implantation. Sacher, Frédéric oth Derval, Nicolas oth Calderon, Joachim oth Barandon, Laurent oth Picard, François oth Haissaguerre, Michel oth Jais, Pierre oth Santos, Pierre Dos oth Enthalten in Elsevier Masson Guan, Xiangyang ELSEVIER A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier 2021 Amsterdam [u.a.] (DE-627)ELV006385559 volume:8 year:2016 number:1 pages:37 https://doi.org/10.1016/S1878-6480(16)30115-X Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 55.82 Güterverkehr VZ AR 8 2016 1 37 045F 610
allfieldsSound	10.1016/S1878-6480(16)30115-X doi GBVA2016011000015.pica (DE-627)ELV019379188 (ELSEVIER)S1878-6480(16)30115-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 380 VZ 55.82 bkl Corré, Jérôme verfasserin aut 0061: Arrhythmic storm in the early phase of Heart Mate® II device implantation. Incidence, risk factors and management 2016transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Rhythmic complications seem common after left ventricular (LV) assist device (LVAD), especially in the early phase of implantation (<30 days). We sought to identify the incidence and risk factors of arrhythmic storm (AS) occuring after Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, CA, USA) implantation. All patients with HM2 implanted in our institution were included. All clinical and ultrasound data were restrospectively collected. Each patient was regurlarly followed until the end of data collection in April 2015. From January 2008 to December 2014, forty-three patients (39 male, 57±11 yo) with severe myocardiopathy (LV Ejection Fraction of 20±5%), mainly ischemic (74%), in bridge to cardiac transplantation (72%), were included. Before implantation, 20 had ICD (16 for prophylaxic indication) and 13 had a prior history of sustained ventricular tachycardia (VT). The overall mortality rate was 60% with a mean follow-up of 18±18 months. 12 patients experienced AS in the first 30 days after implantation, with a median delay of 9±8 days. Early AS often occured in heavier patients (81 vs 69kgs, p<0.05) or with larger body surface area (1.99 vs 1.81m2, p<0.01), in patients with prior sustained VT (50% vs 22%, p=0.08) or long-term treated by betablocker therapy (75% vs 45%, p=0.09). The cardiomyopathy etiology, the indication of assistance or the emergy of implantation were not associated with early AS, as an AS occuring just prior LVAD implantation (11 patients). No AS occured under a Betablocker therapy. VT ablation was performed in 10 patients under assistance. The substrate of VT was not related to HM2 cannula. Arrhythmic storm are frequent (28%) in the early period of HM II implantation. Rhythmic complications seem common after left ventricular (LV) assist device (LVAD), especially in the early phase of implantation (<30 days). We sought to identify the incidence and risk factors of arrhythmic storm (AS) occuring after Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, CA, USA) implantation. All patients with HM2 implanted in our institution were included. All clinical and ultrasound data were restrospectively collected. Each patient was regurlarly followed until the end of data collection in April 2015. From January 2008 to December 2014, forty-three patients (39 male, 57±11 yo) with severe myocardiopathy (LV Ejection Fraction of 20±5%), mainly ischemic (74%), in bridge to cardiac transplantation (72%), were included. Before implantation, 20 had ICD (16 for prophylaxic indication) and 13 had a prior history of sustained ventricular tachycardia (VT). The overall mortality rate was 60% with a mean follow-up of 18±18 months. 12 patients experienced AS in the first 30 days after implantation, with a median delay of 9±8 days. Early AS often occured in heavier patients (81 vs 69kgs, p<0.05) or with larger body surface area (1.99 vs 1.81m2, p<0.01), in patients with prior sustained VT (50% vs 22%, p=0.08) or long-term treated by betablocker therapy (75% vs 45%, p=0.09). The cardiomyopathy etiology, the indication of assistance or the emergy of implantation were not associated with early AS, as an AS occuring just prior LVAD implantation (11 patients). No AS occured under a Betablocker therapy. VT ablation was performed in 10 patients under assistance. The substrate of VT was not related to HM2 cannula. Arrhythmic storm are frequent (28%) in the early period of HM II implantation. Sacher, Frédéric oth Derval, Nicolas oth Calderon, Joachim oth Barandon, Laurent oth Picard, François oth Haissaguerre, Michel oth Jais, Pierre oth Santos, Pierre Dos oth Enthalten in Elsevier Masson Guan, Xiangyang ELSEVIER A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier 2021 Amsterdam [u.a.] (DE-627)ELV006385559 volume:8 year:2016 number:1 pages:37 https://doi.org/10.1016/S1878-6480(16)30115-X Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 55.82 Güterverkehr VZ AR 8 2016 1 37 045F 610
language	English
source	Enthalten in A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier Amsterdam [u.a.] volume:8 year:2016 number:1 pages:37
sourceStr	Enthalten in A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier Amsterdam [u.a.] volume:8 year:2016 number:1 pages:37
format_phy_str_mv	Article
bklname	Güterverkehr
institution	findex.gbv.de
dewey-raw	610
isfreeaccess_bool	false
container_title	A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier
authorswithroles_txt_mv	Corré, Jérôme @@aut@@ Sacher, Frédéric @@oth@@ Derval, Nicolas @@oth@@ Calderon, Joachim @@oth@@ Barandon, Laurent @@oth@@ Picard, François @@oth@@ Haissaguerre, Michel @@oth@@ Jais, Pierre @@oth@@ Santos, Pierre Dos @@oth@@
publishDateDaySort_date	2016-01-01T00:00:00Z
hierarchy_top_id	ELV006385559
dewey-sort	3610
id	ELV019379188
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV019379188</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625125841.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1878-6480(16)30115-X</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016011000015.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV019379188</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1878-6480(16)30115-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">380</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">55.82</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Corré, Jérôme</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">0061: Arrhythmic storm in the early phase of Heart Mate® II device implantation. Incidence, risk factors and management</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Rhythmic complications seem common after left ventricular (LV) assist device (LVAD), especially in the early phase of implantation (<30 days). We sought to identify the incidence and risk factors of arrhythmic storm (AS) occuring after Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, CA, USA) implantation. All patients with HM2 implanted in our institution were included. All clinical and ultrasound data were restrospectively collected. Each patient was regurlarly followed until the end of data collection in April 2015. From January 2008 to December 2014, forty-three patients (39 male, 57±11 yo) with severe myocardiopathy (LV Ejection Fraction of 20±5%), mainly ischemic (74%), in bridge to cardiac transplantation (72%), were included. Before implantation, 20 had ICD (16 for prophylaxic indication) and 13 had a prior history of sustained ventricular tachycardia (VT). The overall mortality rate was 60% with a mean follow-up of 18±18 months. 12 patients experienced AS in the first 30 days after implantation, with a median delay of 9±8 days. Early AS often occured in heavier patients (81 vs 69kgs, p<0.05) or with larger body surface area (1.99 vs 1.81m2, p<0.01), in patients with prior sustained VT (50% vs 22%, p=0.08) or long-term treated by betablocker therapy (75% vs 45%, p=0.09). The cardiomyopathy etiology, the indication of assistance or the emergy of implantation were not associated with early AS, as an AS occuring just prior LVAD implantation (11 patients). No AS occured under a Betablocker therapy. VT ablation was performed in 10 patients under assistance. The substrate of VT was not related to HM2 cannula. Arrhythmic storm are frequent (28%) in the early period of HM II implantation.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Rhythmic complications seem common after left ventricular (LV) assist device (LVAD), especially in the early phase of implantation (<30 days). We sought to identify the incidence and risk factors of arrhythmic storm (AS) occuring after Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, CA, USA) implantation. All patients with HM2 implanted in our institution were included. All clinical and ultrasound data were restrospectively collected. Each patient was regurlarly followed until the end of data collection in April 2015. From January 2008 to December 2014, forty-three patients (39 male, 57±11 yo) with severe myocardiopathy (LV Ejection Fraction of 20±5%), mainly ischemic (74%), in bridge to cardiac transplantation (72%), were included. Before implantation, 20 had ICD (16 for prophylaxic indication) and 13 had a prior history of sustained ventricular tachycardia (VT). The overall mortality rate was 60% with a mean follow-up of 18±18 months. 12 patients experienced AS in the first 30 days after implantation, with a median delay of 9±8 days. Early AS often occured in heavier patients (81 vs 69kgs, p<0.05) or with larger body surface area (1.99 vs 1.81m2, p<0.01), in patients with prior sustained VT (50% vs 22%, p=0.08) or long-term treated by betablocker therapy (75% vs 45%, p=0.09). The cardiomyopathy etiology, the indication of assistance or the emergy of implantation were not associated with early AS, as an AS occuring just prior LVAD implantation (11 patients). No AS occured under a Betablocker therapy. VT ablation was performed in 10 patients under assistance. The substrate of VT was not related to HM2 cannula. Arrhythmic storm are frequent (28%) in the early period of HM II implantation.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sacher, Frédéric</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Derval, Nicolas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Calderon, Joachim</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barandon, Laurent</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Picard, François</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haissaguerre, Michel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jais, Pierre</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santos, Pierre Dos</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Masson</subfield><subfield code="a">Guan, Xiangyang ELSEVIER</subfield><subfield code="t">A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier</subfield><subfield code="d">2021</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV006385559</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:37</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1878-6480(16)30115-X</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">55.82</subfield><subfield code="j">Güterverkehr</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2016</subfield><subfield code="e">1</subfield><subfield code="h">37</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
author	Corré, Jérôme
spellingShingle	Corré, Jérôme ddc 610 ddc 380 bkl 55.82 0061: Arrhythmic storm in the early phase of Heart Mate® II device implantation. Incidence, risk factors and management
authorStr	Corré, Jérôme
ppnlink_with_tag_str_mv	@@773@@(DE-627)ELV006385559
format	electronic Article
dewey-ones	610 - Medicine & health 380 - Commerce, communications & transportation
delete_txt_mv	keep
author_role	aut
collection	elsevier
remote_str	true
illustrated	Not Illustrated
topic_title	610 610 DE-600 380 VZ 55.82 bkl 0061: Arrhythmic storm in the early phase of Heart Mate® II device implantation. Incidence, risk factors and management
topic	ddc 610 ddc 380 bkl 55.82
topic_unstemmed	ddc 610 ddc 380 bkl 55.82
topic_browse	ddc 610 ddc 380 bkl 55.82
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	zu
author2_variant	f s fs n d nd j c jc l b lb f p fp m h mh p j pj p d s pd pds
hierarchy_parent_title	A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier
hierarchy_parent_id	ELV006385559
dewey-tens	610 - Medicine & health 380 - Commerce, communications & transportation
hierarchy_top_title	A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)ELV006385559
title	0061: Arrhythmic storm in the early phase of Heart Mate® II device implantation. Incidence, risk factors and management
ctrlnum	(DE-627)ELV019379188 (ELSEVIER)S1878-6480(16)30115-X
title_full	0061: Arrhythmic storm in the early phase of Heart Mate® II device implantation. Incidence, risk factors and management
author_sort	Corré, Jérôme
journal	A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier
journalStr	A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology 300 - Social sciences
recordtype	marc
publishDateSort	2016
contenttype_str_mv	zzz
container_start_page	37
author_browse	Corré, Jérôme
container_volume	8
class	610 610 DE-600 380 VZ 55.82 bkl
format_se	Elektronische Aufsätze
author-letter	Corré, Jérôme
doi_str_mv	10.1016/S1878-6480(16)30115-X
dewey-full	610 380
title_sort	0061: arrhythmic storm in the early phase of heart mate® ii device implantation. incidence, risk factors and management
title_auth	0061: Arrhythmic storm in the early phase of Heart Mate® II device implantation. Incidence, risk factors and management
abstract	Rhythmic complications seem common after left ventricular (LV) assist device (LVAD), especially in the early phase of implantation (<30 days). We sought to identify the incidence and risk factors of arrhythmic storm (AS) occuring after Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, CA, USA) implantation. All patients with HM2 implanted in our institution were included. All clinical and ultrasound data were restrospectively collected. Each patient was regurlarly followed until the end of data collection in April 2015. From January 2008 to December 2014, forty-three patients (39 male, 57±11 yo) with severe myocardiopathy (LV Ejection Fraction of 20±5%), mainly ischemic (74%), in bridge to cardiac transplantation (72%), were included. Before implantation, 20 had ICD (16 for prophylaxic indication) and 13 had a prior history of sustained ventricular tachycardia (VT). The overall mortality rate was 60% with a mean follow-up of 18±18 months. 12 patients experienced AS in the first 30 days after implantation, with a median delay of 9±8 days. Early AS often occured in heavier patients (81 vs 69kgs, p<0.05) or with larger body surface area (1.99 vs 1.81m2, p<0.01), in patients with prior sustained VT (50% vs 22%, p=0.08) or long-term treated by betablocker therapy (75% vs 45%, p=0.09). The cardiomyopathy etiology, the indication of assistance or the emergy of implantation were not associated with early AS, as an AS occuring just prior LVAD implantation (11 patients). No AS occured under a Betablocker therapy. VT ablation was performed in 10 patients under assistance. The substrate of VT was not related to HM2 cannula. Arrhythmic storm are frequent (28%) in the early period of HM II implantation.
abstractGer	Rhythmic complications seem common after left ventricular (LV) assist device (LVAD), especially in the early phase of implantation (<30 days). We sought to identify the incidence and risk factors of arrhythmic storm (AS) occuring after Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, CA, USA) implantation. All patients with HM2 implanted in our institution were included. All clinical and ultrasound data were restrospectively collected. Each patient was regurlarly followed until the end of data collection in April 2015. From January 2008 to December 2014, forty-three patients (39 male, 57±11 yo) with severe myocardiopathy (LV Ejection Fraction of 20±5%), mainly ischemic (74%), in bridge to cardiac transplantation (72%), were included. Before implantation, 20 had ICD (16 for prophylaxic indication) and 13 had a prior history of sustained ventricular tachycardia (VT). The overall mortality rate was 60% with a mean follow-up of 18±18 months. 12 patients experienced AS in the first 30 days after implantation, with a median delay of 9±8 days. Early AS often occured in heavier patients (81 vs 69kgs, p<0.05) or with larger body surface area (1.99 vs 1.81m2, p<0.01), in patients with prior sustained VT (50% vs 22%, p=0.08) or long-term treated by betablocker therapy (75% vs 45%, p=0.09). The cardiomyopathy etiology, the indication of assistance or the emergy of implantation were not associated with early AS, as an AS occuring just prior LVAD implantation (11 patients). No AS occured under a Betablocker therapy. VT ablation was performed in 10 patients under assistance. The substrate of VT was not related to HM2 cannula. Arrhythmic storm are frequent (28%) in the early period of HM II implantation.
abstract_unstemmed	Rhythmic complications seem common after left ventricular (LV) assist device (LVAD), especially in the early phase of implantation (<30 days). We sought to identify the incidence and risk factors of arrhythmic storm (AS) occuring after Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, CA, USA) implantation. All patients with HM2 implanted in our institution were included. All clinical and ultrasound data were restrospectively collected. Each patient was regurlarly followed until the end of data collection in April 2015. From January 2008 to December 2014, forty-three patients (39 male, 57±11 yo) with severe myocardiopathy (LV Ejection Fraction of 20±5%), mainly ischemic (74%), in bridge to cardiac transplantation (72%), were included. Before implantation, 20 had ICD (16 for prophylaxic indication) and 13 had a prior history of sustained ventricular tachycardia (VT). The overall mortality rate was 60% with a mean follow-up of 18±18 months. 12 patients experienced AS in the first 30 days after implantation, with a median delay of 9±8 days. Early AS often occured in heavier patients (81 vs 69kgs, p<0.05) or with larger body surface area (1.99 vs 1.81m2, p<0.01), in patients with prior sustained VT (50% vs 22%, p=0.08) or long-term treated by betablocker therapy (75% vs 45%, p=0.09). The cardiomyopathy etiology, the indication of assistance or the emergy of implantation were not associated with early AS, as an AS occuring just prior LVAD implantation (11 patients). No AS occured under a Betablocker therapy. VT ablation was performed in 10 patients under assistance. The substrate of VT was not related to HM2 cannula. Arrhythmic storm are frequent (28%) in the early period of HM II implantation.
collection_details	GBV_USEFLAG_U GBV_ELV SYSFLAG_U
container_issue	1
title_short	0061: Arrhythmic storm in the early phase of Heart Mate® II device implantation. Incidence, risk factors and management
url	https://doi.org/10.1016/S1878-6480(16)30115-X
remote_bool	true
author2	Sacher, Frédéric Derval, Nicolas Calderon, Joachim Barandon, Laurent Picard, François Haissaguerre, Michel Jais, Pierre Santos, Pierre Dos
author2Str	Sacher, Frédéric Derval, Nicolas Calderon, Joachim Barandon, Laurent Picard, François Haissaguerre, Michel Jais, Pierre Santos, Pierre Dos
ppnlink	ELV006385559
mediatype_str_mv	z
isOA_txt	false
hochschulschrift_bool	false
author2_role	oth oth oth oth oth oth oth oth
doi_str	10.1016/S1878-6480(16)30115-X
up_date	2024-07-06T21:17:33.647Z
_version_	1803865978200653824
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV019379188</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625125841.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1878-6480(16)30115-X</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016011000015.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV019379188</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1878-6480(16)30115-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">380</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">55.82</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Corré, Jérôme</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">0061: Arrhythmic storm in the early phase of Heart Mate® II device implantation. Incidence, risk factors and management</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Rhythmic complications seem common after left ventricular (LV) assist device (LVAD), especially in the early phase of implantation (<30 days). We sought to identify the incidence and risk factors of arrhythmic storm (AS) occuring after Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, CA, USA) implantation. All patients with HM2 implanted in our institution were included. All clinical and ultrasound data were restrospectively collected. Each patient was regurlarly followed until the end of data collection in April 2015. From January 2008 to December 2014, forty-three patients (39 male, 57±11 yo) with severe myocardiopathy (LV Ejection Fraction of 20±5%), mainly ischemic (74%), in bridge to cardiac transplantation (72%), were included. Before implantation, 20 had ICD (16 for prophylaxic indication) and 13 had a prior history of sustained ventricular tachycardia (VT). The overall mortality rate was 60% with a mean follow-up of 18±18 months. 12 patients experienced AS in the first 30 days after implantation, with a median delay of 9±8 days. Early AS often occured in heavier patients (81 vs 69kgs, p<0.05) or with larger body surface area (1.99 vs 1.81m2, p<0.01), in patients with prior sustained VT (50% vs 22%, p=0.08) or long-term treated by betablocker therapy (75% vs 45%, p=0.09). The cardiomyopathy etiology, the indication of assistance or the emergy of implantation were not associated with early AS, as an AS occuring just prior LVAD implantation (11 patients). No AS occured under a Betablocker therapy. VT ablation was performed in 10 patients under assistance. The substrate of VT was not related to HM2 cannula. Arrhythmic storm are frequent (28%) in the early period of HM II implantation.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Rhythmic complications seem common after left ventricular (LV) assist device (LVAD), especially in the early phase of implantation (<30 days). We sought to identify the incidence and risk factors of arrhythmic storm (AS) occuring after Heart Mate® 2 device (HM2, Thoratec Corporation, Plesanton, CA, USA) implantation. All patients with HM2 implanted in our institution were included. All clinical and ultrasound data were restrospectively collected. Each patient was regurlarly followed until the end of data collection in April 2015. From January 2008 to December 2014, forty-three patients (39 male, 57±11 yo) with severe myocardiopathy (LV Ejection Fraction of 20±5%), mainly ischemic (74%), in bridge to cardiac transplantation (72%), were included. Before implantation, 20 had ICD (16 for prophylaxic indication) and 13 had a prior history of sustained ventricular tachycardia (VT). The overall mortality rate was 60% with a mean follow-up of 18±18 months. 12 patients experienced AS in the first 30 days after implantation, with a median delay of 9±8 days. Early AS often occured in heavier patients (81 vs 69kgs, p<0.05) or with larger body surface area (1.99 vs 1.81m2, p<0.01), in patients with prior sustained VT (50% vs 22%, p=0.08) or long-term treated by betablocker therapy (75% vs 45%, p=0.09). The cardiomyopathy etiology, the indication of assistance or the emergy of implantation were not associated with early AS, as an AS occuring just prior LVAD implantation (11 patients). No AS occured under a Betablocker therapy. VT ablation was performed in 10 patients under assistance. The substrate of VT was not related to HM2 cannula. Arrhythmic storm are frequent (28%) in the early period of HM II implantation.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sacher, Frédéric</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Derval, Nicolas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Calderon, Joachim</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barandon, Laurent</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Picard, François</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haissaguerre, Michel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jais, Pierre</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santos, Pierre Dos</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Masson</subfield><subfield code="a">Guan, Xiangyang ELSEVIER</subfield><subfield code="t">A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier</subfield><subfield code="d">2021</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV006385559</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:37</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1878-6480(16)30115-X</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">55.82</subfield><subfield code="j">Güterverkehr</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2016</subfield><subfield code="e">1</subfield><subfield code="h">37</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
score	7.3967133

Nicht das Richtige dabei?

Schreiben Sie uns!

0061: Arrhythmic storm in the early phase of Heart Mate® II device implantation. Incidence, risk factors and management

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?